Search Results
Your search for Matthew S matches 1058 pages
Showing 951 - 1000Uninsured Young Adults Have Poorer Cancer-Specific Outcomes
The Patient Protection and Affordable Care Act is likely to improve insurance coverage for young adults. In a study reported in the Journal of Clinical Oncology, Aizer et al examined the association between insurance status and cancer outcomes among young adults, finding that the uninsured...
Event-Free Survival Benefit, Greater Toxicity of Augmented Postremission Therapy for Children/Young Adults With High-Risk Acute Lymphoblastic Leukemia
In a UK phase III trial (UKALL 2003) reported in The Lancet Oncology, Vora et al found that augmented postremission therapy provided an event-free survival benefit at the cost of increased toxicity in children and young adults with clinical standard- or intermediate-risk but minimal residual...
Phase III Trial Indicates That S-1 Monotherapy Should Remain Standard Treatment of Locally Advanced Gastric Cancer in Japan
The oral fluoropyrimidine S-1 is standard treatment for locally advanced gastric cancer in Japan. In a Japanese phase III trial (SAMIT) in locally advanced disease reported in The Lancet Oncology, Tsuburaya et al found that sequential paclitaxel plus tegafur and uracil or S-1 did not improve...
Glioma-Associated Antigen Peptide Vaccination Produces Antigen-Specific T-Cell Response and Clinical Activity in Children With High-Grade Gliomas
In a study reported in the Journal of Clinical Oncology, Pollack et al found antigen-specific immune responses and evidence of clinical activity with glioma-associated antigen (GAA) peptide vaccination in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. Study Details In ...
Modeling Shows Digital vs Film Mammography Screening for Breast Cancer Produces Small Benefit at Increased Cost
A study reported in the Journal of the National Cancer Institute by Stout et al suggests that the switch from film to digital mammography screening in the United States has produced a small health benefit at increased cost and with an increased false-positive rate. Biennial digital screening...
MEK Inhibitor Use Associated With Bilateral Subfoveal Neurosensory Retinal Detachment
As reported in JAMA Ophthalmology, McCannel and colleagues identified three cases of subfoveal neurosensory retinal detachment among patients receiving MEK inhibitor therapy for metastatic cancer in clinical trials requiring ophthalmologic examination at their institution. In all cases, the toxic...
Ibrutinib Resistance Mutations Identified in CLL Patients
Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase that was recently approved for treatment of chronic lymphocytic leukemia (CLL) patients who have received at least one prior therapy. A small proportion of CLL patients have been observed to relapse during ibrutinib treatment, ...
Greater Risk of Pretreatment Cognitive Impairment in Older Breast Cancer Patients With More Advanced Disease and Greater Comorbidity
In a study reported in the Journal of Clinical Oncology, Mandelblatt and colleagues attempted to determine whether cognitive impairment is present in older patients with breast cancer prior to systemic therapy. They found that although there were no global differences in cognitive function between...
Percentage Dense Area Stronger Than Absolute Dense Area as Mammography Risk Factor for Breast Cancer
In a meta-analysis reported in the Journal of the National Cancer Institute, Pettersson et al found that percentage dense area on breast mammography is a stronger predictor of breast cancer than absolute dense area. An inverse association of absolute nondense area and risk was also observed. The...
No Overall Survival Improvement With Elacytarabine vs Investigator Choice in Patients With Relapsed/Refractory AML
Current treatment options for relapsed/refractory acute myeloid leukemia (AML), which carries a very poor prognosis, are generally ineffective. In a phase III trial (CLAVELA) reported in the Journal of Clinical Oncology, Roboz et al found that elacytarabine, a novel elaidic acid ester of...
Mutations Associated With Arsenic Resistance in Acute Promyelocytic Leukemia
In a letter to The New England Journal of Medicine, Zhu et al described identification of resistance mutations in acute promyelocytic leukemia patients receiving arsenic trioxide (Trisenox) and all-trans retinoic acid (ATRA) therapy. The direct-binding targets of arsenic trioxide in the...
Low Use of Chemotherapy in Last 14 Days of Life at MD Anderson Cancer Canter
A proposed metric of quality of cancer care is whether chemotherapy is administered in the last 14 days of life. In a retrospective study of patients at The University of Texas MD Anderson Cancer Center reported in JAMA Internal Medicine, Rodriguez et al found an overall rate of chemotherapy use in ...
Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim: Safe and Effective in Muscle-Invasive Urothelial Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Choueiri et al found that a neoadjuvant four-cycle/8-week regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin was well tolerated and effective in patients with muscle-invasive urothelial cancer. Study Details ...
Diffuse Erythema Predicts Complete Remission of Skin Disease With Alemtuzumab in Leukemic Cutaneous T-Cell Lymphoma
As reported in a research letter in JAMA Dermatology, Watanabe et al found that diffuse erythema at presentation in patients with leukemic T-cell lymphoma was associated with better response to low-dose alemtuzumab (Campath) compared with patients presenting with preexisting plaques or tumors....
Squamous Cell Carcinoma Within Advanced Basal Cell Carcinoma During Vismodegib Treatment: Importance of Serial Biopsy
In a report in JAMA Dermatology, Zhu et al discuss two cases in which clinically significant squamous cell carcinoma was found within the tumor bed of locally advanced basal cell carcinoma during vismodegib (Erivedge) treatment for basal cell carcinoma. In one, basal cell carcinoma tumor shrinkage...
No Difference in Postsurgery Fatigue With Laparoscopic vs Open Surgery for Colorectal Cancer With Enhanced Recovery Program
In a UK trial (EnROL) reported in the Journal of Clinical Oncology, Kennedy et al compared outcomes with open vs laparoscopic resection of colorectal cancer within a multimodality enhanced recovery program. Such programs are intended to improve all aspects of perioperative care and have been shown...
False-Positive Screening Mammograms Associated With Short-Term Anxiety but No Reduced Intention to Undergo Subsequent Mammography
The effect of false-positive mammograms on women undergoing screening is being investigated by the U.S. Preventive Services Task Force. In a study reported in JAMA Internal Medicine, Tosteson et al assessed responses to false-positive screening mammograms. According to the authors, their findings...
Ado-Trastuzumab Emtansine Improves Progression-Free Survival vs Physician’s Choice in Previously Treated Advanced HER2-Positive Breast Cancer
There are few treatment options for breast cancer patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic disease. In the open-label phase III TH3RESA trial reported in The Lancet Oncology by Krop and et al, ado-trastuzumab emtansine (Kadcyla)...
ASCO Releases Companion Guideline on Disease Management for Patients With Advanced HER2-Positive Breast Cancer and Brain Metastases
As many as half of patients with metastatic HER2-positive breast cancer develop brain metastases over time. The American Society of Clinical Oncology recently released a clinical practice guideline on disease management for patients with advanced HER2-positive breast cancer and brain metastases. A...
Final Overall Survival Results Show No Difference for Pazopanib vs Sunitinib in First-Line Treatment of Clear Cell Metastatic Renal Cell Carcinoma
A phase III trial reported in 2013 showed noninferiority of pazopanib (Votrient) vs sunitinib (Sutent) for progression-free survival in first-line treatment of clear cell metastatic renal cell carcinoma. In a letter to the editor in The New England Journal of Medicine, Motzer et al provided the...
Anti–Interleukin-1 Alpha Antibody MABp1 Is Well Tolerated, Safe, and Active in Phase I Trial in Refractory Cancers
Expression of the inflammatory cytokine interleukin (IL)-1 alpha is a very early step in the inflammatory response that characterizes the malignant phenotype and that is associated with angiogenesis, tumor invasiveness, metastasis, and cachexia. In a phase I dose-escalation study reported in The...
Cumulative Risk of Breast Cancer Reaches 30% by Age 50 After Chest Irradiation for Childhood Cancer
The incidence of breast cancer in women treated with chest radiation therapy for childhood cancer previously has been estimated at 5% to 14% by age 40 years and is among the highest reported for any population. In a study reported in the Journal of Clinical Oncology, Moskowitz et al found that the...
No Difference in Disease-Free Survival but Less Steroid Dependence With Adrenal-Sparing Surgery vs Adrenalectomy in Pheochromocytoma
Molecular diagnosis and preventive surgery have been successful in preventing medullary thyroid cancer in patients with multiple endocrine neoplasia type 2 syndrome. In a retrospective population-based study reported in The Lancet Oncology, Castinetti et al found no difference in disease-free...
Sorafenib Improves Progression-Free Survival in Progressive Radioactive Iodine–Refractory Differentiated Thyroid Cancer
Patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer have a poor prognosis. In the double-blind phase III DECISION trial reported in The Lancet, Brose et al found that sorafenib (Nexavar) increased progression-free survival in this setting. The...
Breast Cancer Risk Variant Associated With Increased Lung Cancer Risk in Women
In a study reported in the Journal of the National Cancer Institute, Park et al examined single nucleotide polymorphisms (SNPs) associated with other cancers for potential associations with lung cancer. They found that the breast cancer SNP LSP1 rs3817198 was associated with significant risk of...
Quality-of-Life Study in NCIC MAP.3 Trial Shows Limited Negative Impact of Daily Exemestane in Breast Cancer Prevention
The National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Prevention 3) trial showed that daily exemestane treatment reduced invasive breast cancer risk by 65% among postmenopausal women. In a quality-of-life study in the MAP.3 population reported in the Journal of...
ASCO Releases Adapted Guideline on Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer
A majority of cancer patients experience some level of fatigue during their course of treatment, and approximately 30% contend with persistent fatigue for years after treatment. Fatigue is among the most common and distressing long-term effects of cancer treatment and significantly affects patient...
ASCO Issues Adapted Guideline on Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer
ASCO has adapted the Pan-Canadian Practice Guideline on Screening, Assessment, and Care of Psychosocial Distress (Depression, Anxiety) in Adults With Cancer for use in the screening, assessment, and care of anxiety and depressive symptoms in adults with cancer. The adapted guideline, reported in...
IGH@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia
In a study reported in the Journal of Clinical Oncology, Russell et al found that immunoglobulin heavy chain (IGH@) translocations were present in a substantial proportion of younger patients with acute lymphoblastic leukemia (ALL), including those with B-cell precursor ALL. However, IGH@...
Consumptive Hypothyroidism in GIST Associated With Increased D3 Expression
In a report in The New England Journal of Medicine, Maynard et al discuss identification of consumptive hypothyroidism due to overexpression of thyroid hormone–inactivating enzyme type 3 iodothyronine deiodinase (D3) in a patient with gastrointestinal stromal tumor (GIST) and subsequent...
Similar Progression-Free Survival With Panitumumab vs Bevacizumab Plus Modified FOLFOX6 in Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
In a phase II trial (PEAK) reported in the Journal of Clinical Oncology, Schwartzberg et al compared the EGFR inhibitor panitumumab (Vectibix) vs the VEGF-A inhibitor bevacizumab (Avastin) combined with modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) in patients with previously...
Radiofrequency Ablation Reduces Risk of High-Grade Dysplasia and Adenocarcinoma vs Endoscopic Surveillance in Patients With Barrett’s Esophagus
Barrett’s esophagus with low-grade dysplasia increases risk of esophageal adenocarcinoma. In a European study reported in JAMA, Phoa et al assessed whether endoscopic radiofrequency ablation reduced the rate of neoplastic progression compared with endoscopic surveillance in patients with...
Locoregional Progression of Cervical Cancer Follows Reverse Ontogenetic Sequence
In a study reported in The Lancet Oncology, Höckel et al demonstrated that locoregional progression of cervical cancer follows the reverse sequence of establishment of adult tissues in ontogeny. Ontogenetic staging was a better predictor of survival than pathologic staging. Previous work by...
Phase II Study Suggests Benefit of Adding Rituximab to Chlorambucil in First-Line Treatment for Chronic Lymphocytic Leukemia
In a UK phase II study reported in the Journal of Clinical Oncology, Hillmen et al assessed the safety and activity of adding rituximab (Rituxan) to chlorambucil (Leukeran) in first-line treatment of chronic lymphocytic leukemia (CLL). Such a regimen may be an alternative to fludarabine-based...
Analysis of SWOG Trials Indicates No Survival Difference After 1 Year in Cancer Patients Treated In vs Out of Clinical Trials
In a study reported in the Journal of the National Cancer Institute, Unger et al evaluated whether cancer patients from SWOG clinical trials were similar to nontrial patients in baseline characteristics and survival. They found that, overall, trial participation in standard treatment arms did not...
Children With Cancer, Parents, and Providers Value Patient-Reported Outcomes Feedback
In a pilot trial (PediQUEST) reported in the Journal of Clinical Oncology, Wolfe et al assessed the effects of use of the PediQUEST electronic patient-reported feedback survey on health-related quality of life in children with advanced cancer. Although few significant improvements were observed,...
Pilot Study Shows Decision Aid Helps in Decision-Making Regarding Mammography Screening in Women Aged ≥ 75 Years
Although it is recommended that women aged ≥ 75 years be informed of the benefits and risks of mammography before being screened, it appears that this is not common practice. As reported in JAMA Internal Medicine by Schonberg et al, a decision aid developed by the investigators helped improved...
Fertility Concerns Affect Treatment Choices in Young Women With Breast Cancer, but Few Use Preservation Options
Little is known about how fertility concerns affect treatment decisions or fertility preservation strategies at the time of initial diagnosis of breast cancer. In an ongoing multicohort study reported in the Journal of Clinical Oncology, Ruddy et al found that most young women with breast cancer...
Screening With Visual Inspection of Cervix After 4% Acetic Acid Could Reduce Cervical Cancer Mortality by 22,000 per Year in India
Cervical cancer is the leading cause of cancer death in women in India, a nation where large-scale Pap smear screening is not feasible. As reported in the Journal of the National Cancer Institute, Shastri et al have performed a large cluster-randomized study of education and screening of Indian...
‘Real World’ Safety Study of Vemurafenib in BRAF V600–Mutated Metastatic Melanoma Shows Similar Safety Profile as Pivotal Trials
As reported in The Lancet Oncology by Larkin et al, interim results of a safety study designed to reflect the spectrum of patients encountered in routine practice suggest that vemurafenib (Zelboraf) has a safety profile in patients with BRAF V600–mutated metastatic melanoma similar to that...
Study Finds Possible New Gene Target for Lung Cancer
Researchers have identified a potential new gene mutation that may drive lung cancer development and growth. In a study in the Journal of Clinical Investigation by Imielinski et al, a patient with advanced lung cancer who was found to have the ARAF S214Csomatic gene mutation achieved nearly a...
Adding Bevacizumab to Chemotherapy Improves Survival in Advanced Cervical Cancer
Retreatment with cisplatin has reduced effectiveness in patients with recurrent cervical cancer who have received cisplatin with radiation therapy. In a 2×2 factorial phase III trial reported in The New England Journal of Medicine, Tewari et al compared cisplatin/paclitaxel vs nonplatinum...
Methotrexate-Induced Neurotoxicity Does Not Preclude Rechallenge in Children With ALL
In a study reported in the Journal of Clinical Oncology, Bhojwani et al from St. Jude Children’s Research Hospital assessed clinical, pharmacokinetic, and genetic risk factors for methotrexate-related clinical neurotoxicity and asymptomatic leukoencephalopathy in children with acute...
SSO-ASTRO Consensus Guideline: Margins Wider Than 'No Ink on Tumor' Do Not Further Reduce Risk of Ipsilateral Breast Tumor Recurrence
The Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) formed a multidisciplinary expert panel in 2013 to examine the relationship between surgical margin width and ipsilateral breast tumor recurrence and develop guidelines on margins for breast-conserving...
Coordination of Care Improves Patient-Reported Quality of Supportive Care Among Patients With Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, van Ryn et al assessed patient-reported quality of care among patients with colorectal cancer in the Veterans Affairs health-care system. The investigators found significant gaps in patient-centered quality of supportive care, but also found...
Progression-Free Survival Can Be Used as Surrogate for Overall Survival in Metastatic Melanoma Trials With Dacarbazine Control Group
In a meta-analysis reported in The Lancet Oncology, Flaherty et al found that progression-free survival is a reliable surrogate for overall survival in clinical trials in metastatic melanoma that include dacarbazine as control treatment. Study Details In the analysis, 1,649 reports and meeting...
Hyaluronan Synthase 3 Variant Associated With Increased Risk of Anthracycline-Related Cardiomyopathy
In a study reported in the Journal of Clinical Oncology, Wang et al in the Children’s Oncology Group identified a common single nucleotide polymorphism, rs2232228, in the hyaluronan synthase 3 (HAS3) gene that is associated with anthracycline dose–related risk of cardiomyopathy in...
Is the Traumatic Impact of Cancer Overestimated in Children With Cancer?
In a study reported in the Journal of Clinical Oncology, Phipps et al found no evidence of increased post-traumatic stress disorder (PTSD) or post-traumatic stress symptoms (PTSS) in children with cancer and observed a heightened sense of perceived growth related to cancer events in these children. ...
Telephone-Based Intervention Improves Colorectal Cancer Screening in At-Risk Relatives of Patients With Colorectal Cancer
Individuals at increased familial risk of colorectal cancer have poor adherence to colonoscopy screening recommendations, especially those in rural and other geographically underserved populations. In a study (Family CARE trial) reported in the Journal of Clinical Oncology, Kinney et al found that...
PI3K-Delta Inhibitor Idelalisib Produces High Response Rates in Relapsed Indolent Lymphoma
Phosphatidylinositol 3-kinase (PI3K)-delta mediates B-cell receptor signaling and microenvironment support signals that promote the growth and survival of malignant B lymphocytes. In a phase II study reported in The New England Journal of Medicine, Gopal et al found that the PI3K-delta inhibitor...
